Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

After second attempt, Argos Therapeutics finalizes $46.3mm IPO on Nasdaq

Executive Summary

Cancer and infectious disease immunotherapy company Argos Therapeutics Inc. netted $46.3mm through an IPO of 6.2mm shares (including partial exercise of the overallotment) at $8, selling more shares than the 4.25mm it originally expected, when it filed in December 2013, but below its proposed $13-15 range. In Argos’ first attempt to go public in July 2011, it set terms at 5.25mm shares with a $13-15 price range, but withdrew the offering in March 2012 due to poor market conditions.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register